NantHealth, Inc. (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) will cover the GPS Cancer test for its members enrolled in investigational studies for key cancer types—non-small cell lung cancer, breast cancer, colon cancer, cancer of unknown primary—across leading health systems in the mid-Atlantic. These institutions include the Hospital of University of Pennsylvania (HUP), Cancer Institute of New Jersey, Hackensack Medical Center, Meridian Hospital and Regional Cancer Care Associates LLC (RCCA), who will also utilize COTA, Inc.'s analytics solution to monitor and track differences in clinical outcomes and cost-analysis throughout these investigational efforts. Horizon BCBSNJ will sponsor the GPS Cancer tests for a sample of up to 150 eligible patients. "This is a significant milestone for NantHealth and we are excited about this partnership with Horizon, the largest payer in New Jersey and second major Blues plan to cover GPS Cancer, and COTA," stated Patrick Soon-Shiong, MD, founder and CEO of NantHealth and founder of the Cancer MoonShot 2020 initiative. "With these institutions, we're working to pioneer change for cancer patients by arming providers with the most valuable and relevant information. With GPS Cancer, New Jersey-area oncologists will have access to cutting-edge genomic sequencing and proteomics capabilities that will help them guide treatment strategies before therapy begins, thereby enabling the delivery of higher quality, more cost-effective care for their patients." GPS Cancer, a comprehensive molecular test offered by NantHealth, integrates quantitative proteomics with whole genome (DNA) and transcriptome (RNA) sequencing, to provide oncologists with a comprehensive molecular profile of a patient's cancer to inform personalized treatment strategies. As a cornerstone of the Cancer MoonShot 2020 program, GPS Cancer provides the critical insights based on the unique biology of a patient's tumor—from the DNA to the RNA to the protein. The richness of this information helps doctors build more effective treatment plans based on FDA-approved drugs and active clinical trials, while enabling cancer researchers to design new clinical trials that harness the potential of the immune system. "Horizon is committed to collaborating with medical leaders and leveraging new clinical technologies to help our 3.8 million members defeat cancer," said Allen Karp, senior vice president of Healthcare Management for Horizon BCBSNJ.